|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TIAM2 |
Gene summary for TIAM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TIAM2 | Gene ID | 26230 |
| Gene name | TIAM Rac1 associated GEF 2 | |
| Gene Alias | STEF | |
| Cytomap | 6q25.2-q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q8IVF5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26230 | TIAM2 | AEH-subject1 | Human | Endometrium | AEH | 2.36e-08 | 3.13e-01 | -0.3059 |
| 26230 | TIAM2 | AEH-subject3 | Human | Endometrium | AEH | 2.08e-05 | 2.91e-01 | -0.2576 |
| 26230 | TIAM2 | AEH-subject4 | Human | Endometrium | AEH | 1.49e-03 | 2.58e-01 | -0.2657 |
| 26230 | TIAM2 | AEH-subject5 | Human | Endometrium | AEH | 5.69e-16 | 4.43e-01 | -0.2953 |
| 26230 | TIAM2 | EEC-subject1 | Human | Endometrium | EEC | 1.10e-06 | 3.30e-01 | -0.2682 |
| 26230 | TIAM2 | EEC-subject2 | Human | Endometrium | EEC | 2.21e-06 | 3.06e-01 | -0.2607 |
| 26230 | TIAM2 | EEC-subject4 | Human | Endometrium | EEC | 2.43e-06 | 3.08e-01 | -0.2571 |
| 26230 | TIAM2 | EEC-subject5 | Human | Endometrium | EEC | 2.70e-10 | 3.57e-01 | -0.249 |
| 26230 | TIAM2 | 047563_1562-all-cells | Human | Prostate | BPH | 1.04e-04 | 2.75e-01 | 0.0791 |
| 26230 | TIAM2 | 048752_1579-all-cells | Human | Prostate | BPH | 2.59e-27 | 5.88e-01 | 0.1008 |
| 26230 | TIAM2 | 052095_1628-all-cells | Human | Prostate | BPH | 1.68e-11 | 3.99e-01 | 0.1032 |
| 26230 | TIAM2 | 052097_1595-all-cells | Human | Prostate | BPH | 6.80e-12 | 3.50e-01 | 0.0972 |
| 26230 | TIAM2 | 052099_1652-all-cells | Human | Prostate | BPH | 2.75e-20 | 5.18e-01 | 0.1038 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00074098 | Endometrium | AEH | axonogenesis | 81/2100 | 418/18723 | 5.54e-07 | 2.12e-05 | 81 |
| GO:00615648 | Endometrium | AEH | axon development | 88/2100 | 467/18723 | 6.39e-07 | 2.38e-05 | 88 |
| GO:00430878 | Endometrium | AEH | regulation of GTPase activity | 66/2100 | 348/18723 | 1.26e-05 | 2.77e-04 | 66 |
| GO:00510567 | Endometrium | AEH | regulation of small GTPase mediated signal transduction | 59/2100 | 302/18723 | 1.43e-05 | 3.03e-04 | 59 |
| GO:00107207 | Endometrium | AEH | positive regulation of cell development | 57/2100 | 298/18723 | 3.72e-05 | 6.49e-04 | 57 |
| GO:00109758 | Endometrium | AEH | regulation of neuron projection development | 75/2100 | 445/18723 | 2.01e-04 | 2.54e-03 | 75 |
| GO:00435477 | Endometrium | AEH | positive regulation of GTPase activity | 48/2100 | 255/18723 | 2.18e-04 | 2.67e-03 | 48 |
| GO:00313468 | Endometrium | AEH | positive regulation of cell projection organization | 61/2100 | 353/18723 | 3.91e-04 | 4.20e-03 | 61 |
| GO:00507725 | Endometrium | AEH | positive regulation of axonogenesis | 17/2100 | 79/18723 | 5.93e-03 | 3.59e-02 | 17 |
| GO:00906304 | Endometrium | AEH | activation of GTPase activity | 22/2100 | 115/18723 | 8.42e-03 | 4.60e-02 | 22 |
| GO:00507677 | Endometrium | AEH | regulation of neurogenesis | 56/2100 | 364/18723 | 8.87e-03 | 4.82e-02 | 56 |
| GO:006156412 | Endometrium | EEC | axon development | 93/2168 | 467/18723 | 9.60e-08 | 4.69e-06 | 93 |
| GO:000740912 | Endometrium | EEC | axonogenesis | 82/2168 | 418/18723 | 1.03e-06 | 3.49e-05 | 82 |
| GO:005105612 | Endometrium | EEC | regulation of small GTPase mediated signal transduction | 61/2168 | 302/18723 | 9.42e-06 | 2.08e-04 | 61 |
| GO:004308712 | Endometrium | EEC | regulation of GTPase activity | 67/2168 | 348/18723 | 1.84e-05 | 3.43e-04 | 67 |
| GO:001097513 | Endometrium | EEC | regulation of neuron projection development | 79/2168 | 445/18723 | 6.80e-05 | 1.01e-03 | 79 |
| GO:004354712 | Endometrium | EEC | positive regulation of GTPase activity | 50/2168 | 255/18723 | 1.26e-04 | 1.66e-03 | 50 |
| GO:001072012 | Endometrium | EEC | positive regulation of cell development | 56/2168 | 298/18723 | 1.68e-04 | 2.10e-03 | 56 |
| GO:003134613 | Endometrium | EEC | positive regulation of cell projection organization | 61/2168 | 353/18723 | 8.82e-04 | 8.03e-03 | 61 |
| GO:009063012 | Endometrium | EEC | activation of GTPase activity | 23/2168 | 115/18723 | 6.04e-03 | 3.57e-02 | 23 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TIAM2 | SNV | Missense_Mutation | c.392G>C | p.Arg131Thr | p.R131T | Q8IVF5 | protein_coding | tolerated_low_confidence(0.09) | benign(0.054) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| TIAM2 | SNV | Missense_Mutation | rs374985070 | c.3691C>T | p.Arg1231Trp | p.R1231W | Q8IVF5 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
| TIAM2 | SNV | Missense_Mutation | c.4771C>A | p.Gln1591Lys | p.Q1591K | Q8IVF5 | protein_coding | deleterious(0.01) | possibly_damaging(0.877) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TIAM2 | SNV | Missense_Mutation | rs756072856 | c.424G>A | p.Gly142Arg | p.G142R | Q8IVF5 | protein_coding | deleterious_low_confidence(0.05) | benign(0.048) | TCGA-AC-A3OD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TIAM2 | SNV | Missense_Mutation | rs182530977 | c.784N>A | p.Glu262Lys | p.E262K | Q8IVF5 | protein_coding | deleterious(0) | benign(0.255) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
| TIAM2 | SNV | Missense_Mutation | rs767995840 | c.617N>T | p.Ser206Leu | p.S206L | Q8IVF5 | protein_coding | deleterious_low_confidence(0.01) | benign(0.057) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
| TIAM2 | SNV | Missense_Mutation | c.1735C>G | p.Pro579Ala | p.P579A | Q8IVF5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| TIAM2 | SNV | Missense_Mutation | c.5054N>G | p.Ser1685Cys | p.S1685C | Q8IVF5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TIAM2 | SNV | Missense_Mutation | novel | c.3533N>T | p.Ser1178Leu | p.S1178L | Q8IVF5 | protein_coding | tolerated(0.06) | possibly_damaging(0.718) | TCGA-EW-A6SA-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TIAM2 | SNV | Missense_Mutation | novel | c.3175G>A | p.Glu1059Lys | p.E1059K | Q8IVF5 | protein_coding | deleterious(0.02) | benign(0.219) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |